1 26

4 4 9 9 0 8 1

P E P T I D E C O M P O U N D S

PATENT ABSTRACTS

Ole D Laerum, Bergen, Norway assigned to Nyegaard & Co A/S

HN C H - - C O N H ~ C H - - C O N H ~ C H - - C O N H -- I I

(CH2)2 CH2 o ~ I J

COX I COOH

- - C H - - C O ( N H - - R I - - C O ) n N H C H - - C O X 2 I I CH2 (CH2)4 I I SFI NH2

The invention provides compounds of the gene- ral formula: See Patent for Chemical Structure See Patent for Tabular Presentation (in which RI is the residue of glycine or D-alanine, and all other amino-acid residues are in the L-form, XI and X2, which may be the same or different, are OH or NH2 and n is 0 or l) and their phys- iologically acceptable salts. The compounds of the invention are capable of inhibiting the myelopoietic system of humans and animals, thereby protecting said system against attack by cytotoxic drugs.

4 5 0 0 4 5 1

N E W P R O T E I N P P 1 3 E X T R A C T E D F R O M H U M A N P L A C E N T A L

T I S S U E S A N D U S E T H E R E O F

Hans Bohn, Walter Kraus, Marburg, Federal Republic Of Germany assigned to Behringwerke Aktiengesellschaft

Protein PPI3 is isolated from human placental tissues using a variety of methods, e.g., immuno- adsorption. The protein has utility in production of an antiserum which has diagnostic applica- tions. The placental specific proteins (e.g., PP13) are frequently detected in increasing amounts in women as pregnancy advances, and in patients with tumors especially of the tryphoblastic and embryonal types.

4 5 0 0 5 0 8

R A D I O N U C L I D E L A B E L E D L Y M P H O C Y T E S F O R T H E R A P E U T I C U S E

Suresh C Srivastava, Rashid Fawwaz, Powel Richards assigned to The United States of America as represented by the United States Department of Energy

Lymphocytes labelled with beta-emitting

radionuclides are therapeutically useful, par- ticularly for lymphoid ablation. They are pre- pared by incubation of the lymphocytes with the selected radionuclide-oxine complex.

4 5 0 0 5 1 3

I N F L U E N Z A V A C C I N E P R O D U C T I O N IN L I Q U I D C E L L

C U L T U R E

Karen K Brown, Richard Stewart assigned to Miles Laboratories Inc

Infectivity and replication of influenza viruses in successive numbers of cells of the same liquid cell culture is assured by including a protein hydro- lyzing enzyme in the culture during virus incuba- tion. Technique overcomes one-step growth cycle of virus and allows commercial influenza vaccine production from liquid cell cultures in- stead of from more costly embryonated chicken eggs. Resulting vaccine is thus substantially free of egg proteins.

4 5 0 0 6 3 7

P R E V E N T I O N O F G R A F T V E R S U S H O S T D I S E A S E F O L L O W I N G

B O N E M A R R O W T R A N S P L A N T A T I O N

David M Neville, Richard J Youle assigned to The United States of America as represented by the Department of Health and Human Services

A monoclonal antibody known as TA-1 directed against human T-cells is covalently linked to the toxin ricin and used to treat human donor bone marrow before the marrow is infused into a human recipient.

4 5 0 1 6 9 2

C H A R G E E F F E C T S IN E N Z Y M E I M M U N O A S S A Y S

fan Gibbons, Gerald L Rowley, Edwin F Ull- man assigned to Syva Company

PATENT

A method for determining a member of a specific binding pair-ligand and receptor (anti- ligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more compo- nents. The average proximity in the assay medium of the first and second modified mem- bers is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system. Also, com- positions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

ABSTRACTS

4501744

127

S U B S T I T U T E D - A Z A - C Y T O S I N E C O M P O U N D S A N D A N T I - V I R A L

U S E S T H E R E O F

Kelvin K Ogilvie, Candiac, Canada assigned to ens BIO LOGICALS Inc

Nucleoside analogues having a ring-open struc- ture, of general formula: See Patent for Chemical Structure where R and R' may be hydrogen, silyl groups, substituted alkyl groups, benzyl groups and the like, and X is an optionally substituted pyrimidine or triazine base, exhibit anti-viral ac- tivities e.g. against herpes simplex virus and cytomegalo-virus at non-toxic levels.

4501693

M E T H O D O F P R E P A R I N G I M M U N O S T I M U L A N T

P R O T E O G L Y C A N S W H I C H I N D U C E P R O D U C T I O N O F

I N T E R F E R O N , P R O T E O G L Y C A N S O B T A I N E D A N D

P H A R M A C E U T I C A L C O M P O S I T I O N S C O N T A I N I N G

T H E M

d'Hinterland Lucien Dussourd, Gerard Nor- mier, Anne-Marie Pinel, Castres, France as- signed to Pierre Fabre S A

The present invention relates to a method of pre- paring bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram- negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product. The products obtained are useful as a medicament.

4503030

D E V I C E F O R D E L I V E R I N G D R U G T O C E R T A I N P H E N V I R O N M E N T S

David Edgren, Patrick S L Wong, Felix Theeuwes assigned to ALZA Corporation

An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second en- vironment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first en- vironment and loses its integrity in the second environment.

L × QD I T" "7" x -'b'~

4501728

M A S K I N G O F L I P O S O M E S F R O M R E S R E C O G N I T I O N

W Blair Geho, John R Lau assigned to Tech- nology Unlimited Inc

A biochemical membrane covered with sialic residues thereby provides a coating that masks the surface membrane from recognition and removal by the scavenging RES cells of the body.

4503035

P R O T E I N P U R I F I C A T I O N P R O C E S S A N D P R O D U C T

Sidney Pestka, Menache Rubinstein assigned to Hoffmann-La Roche Inc

An improved process for purifying proteins, particularly proteins having molecular weights in excess of 12,000 involves novel applications of high performance liquid chromatography on a